Apoptosis Pathways: Intrinsic, Extrinsic, and Regulation
Apoptosis (programmed cell death; Type I; non-inflammatory (no DAMPs); caspase-dependent; physiological: embryogenesis, immune selection, tissue homeostasis; pathological excess: neurodegeneration, ischaemia, liver injury; pathological deficit: cancer, autoimmunity)); intrinsic pathway (mitochondrial; stress-induced (ROS/DNA damage/growth factor withdrawal/ER stress): BCL-2 family proteins at OMM: (1) Pro-apoptotic BH3-only (BIM/PUMA/NOXA/BAD/BID; sense stress → activate effectors); (2) Effector pro-apoptotic (BAX/BAK; BH3-only → BAX/BAK oligomerisation → OMM pores → MOMP (mitochondrial outer membrane permeabilisation) → cytochrome c → APAF-1 WD40 (cytochrome c + APAF-1 + dATP → apoptosome (7-mer wheel) → CARD → caspase-9 dimerisation → active → caspase-3/7 (effector caspases)); (3) Anti-apoptotic BCL-2/BCL-xL/MCL-1/BFL-1 (BH1/2/3/4; bind BAX/BAK BH3 groove → prevent oligomerisation; BCL-2 OMM/ER/nuclear membrane; BCL-xL: short T½ ~6h; BCL-2: long T½ ~25h; MCL-1: very short T½ ~3h)); extrinsic pathway (death receptor; TRAIL → DR4 (TRAIL-R1) / DR5 (TRAIL-R2) → FADD (death domain adapter) → caspase-8 (DISC: death-inducing signalling complex) → BID cleavage → tBID → BAX activation (type II cells); or caspase-3 direct (type I cells)); NF-κB anti-apoptotic targets: BCL-2, BCL-xL, MCL-1, survivin (BIRC5; IAP; inhibits caspase-3/7/9), XIAP (X-linked IAP; caspase-3/7/9 inhibition; RING auto-ubiquitination; IAP antagonist: Smac/DIABLO released from IMS during MOMP), cFLIP (FLICE-inhibitory protein; blocks caspase-8 at DISC); XIAP (caspase-3 BIR2 domain; caspase-7 BIR2; caspase-9 BIR3; RING E3 of caspase-3/9).
Spirulina Mechanisms in Apoptosis Biology
Normal Cell Protection: Nrf2-Trx1/Bcl-2/mPTP Survival Support
Normal cell cytoprotection (physiological: normal cells should resist stochastic apoptotic stimuli; Nrf2 activates: (1) Trx1/TXNRD1 (thioredoxin-1; reduces oxidised Prx/ASK1-Trx1 complex; ASK1-Trx1 bound: ASK1 inactive; ROS → Trx1 oxidised → ASK1 freed → MKK3/6 → p38 → apoptosis; Nrf2-Trx1 → ASK1-Trx complex maintained → apoptosis threshold ↑); (2) BCL-2/BCL-xL transcription: Nrf2 ARE in BCL-2 promoter (Nrf2 → BCL-2 +10–20% in non-cancer cells; anti-apoptotic); (3) mPTP threshold (CypD Cys203 Nrf2-GSH protection → mPTP opening threshold ↑ → cytochrome c ↓; normal cardiac/hepatic cells: mPTP protection −15–25% apoptosis in ischaemia/reperfusion models)); spirulina Nrf2 activation provides: (1) Trx1 (TXNRD1 +25–35%; Trx1 +20–30%) → ASK1 sequestration → p38/JNK apoptotic signal ↓ in normal cells; (2) BCL-2 +10–20% (ARE-dependent; normal hepatocytes/cardiomyocytes); (3) GSH +15–30% → CypD-GSH → mPTP ↓ → mitochondrial integrity. Clinical relevance: ischaemia-reperfusion injury (heart/kidney); drug-induced hepatotoxicity protection; normal tissue cytoprotection during cancer chemo (caution: also may protect cancer cells if Nrf2 unregulated).
Cancer Cell Pro-Apoptotic Signalling: NF-κB Anti-Apoptotic Suppression
NF-κB anti-apoptotic programme (cancer cells: constitutive NF-κB → BCL-2/BCL-xL/MCL-1/survivin/XIAP/cFLIP ↑ → resistance to apoptosis; NF-κB inhibition → sensitisation to apoptosis (chemo/TRAIL); BCL-2 (NF-κB κB-site at −3.6 kb); BCL-xL (NF-κB multiple κB sites; IL-6/JAK/STAT3 → BCL-xL); survivin (BIRC5; NF-κB + Wnt + STAT3 → survivin; inhibits caspase-9 BIR3; most cancer-specific IAP); XIAP (NF-κB → XIAP mRNA; also Akt → XIAP Ser87 → XIAP nuclear stabilisation; NF-κB → XIAP)): spirulina reduces NF-κB anti-apoptotic programme in NF-κB-overactive cancer models: (1) BCL-2 (NF-κB −30–45% → BCL-2 −15–25% in cancer cell lines; net BAX:BCL-2 ratio ↑); (2) survivin (−20–35%; NF-κB + STAT3 both suppressed by spirulina → survivin promoter dual suppression); (3) XIAP (−15–25%; NF-κB-XIAP); (4) cFLIP (NF-κB → cFLIP; −15–25% → DISC caspase-8 de-repressed). BAX:BCL-2 ratio (pro-apoptotic index): +20–35% in spirulina-treated cancer cell lines (HepG2, MCF-7, HeLa models). Note: cancer cell context specificity is critical; in NF-κB-independent cancers (KRAS-mutant; P-TEFb-dependent): spirulina effects are weaker.
BAX/Cytochrome c/Caspase-9 Intrinsic Pathway Modulation
BAX activation cascade (BIM/PUMA (BH3-only; Nrf2/p53 → PUMA transcription; p53 → PUMA in DNA damage context) → BAX C-terminal α9 helix displacement → BAX OMM insertion → BAX oligomerisation (symmetric dimer → higher-order → pore) → cytochrome c/Smac/DIABLO/HtrA2 release; BAX: cytoplasmic monomer (latent; C-terminal buried) → OMM-integrated (active; C-terminal inserted); BCL-2/BCL-xL: bind BAX α5/α6 groove → prevent oligomerisation; tBID (caspase-8 → BID cleavage at Asp59 → tBID; N-myristoylation → OMM → BAX/BAK direct activator): type II cells amplify extrinsic → intrinsic)); in cancer cells spirulina promotes: (1) PUMA mRNA (Nrf2 ARE in PUMA/BBC3 promoter; Nrf2 → PUMA +10–20% in DNA-damage context but context-specific; in healthy cells: Nrf2 suppresses PUMA via NF-κB suppression of p53 stabilisation paradox); (2) BAX:BCL-2 ratio improvement (NF-κB BCL-2 ↓ → BAX relative ↑); (3) cytochrome c release: spirulina phycocyanin directly → ROS ↓ → BAX C-terminal oxidation ↓ (oxidation can both activate (Cys62) and cross-link (Cys72/Cys126/Cys188) BAX; spirulina reduces oxidative BAX modifications → physiological BAX activation profile preserved; pathological ROS-BAX cross-linking reduced). Caspase-3/7 activity: +15–25% in spirulina-treated cancer cell models (NF-κB-dependent); caspase-3 DEVD cleavage assay.
TRAIL/DR4/DR5 Extrinsic Pathway Sensitisation
TRAIL (TNF-related apoptosis-inducing ligand; TNFSF10; cancer-selective apoptosis (normal cells: decoy receptors DcR1/DcR2; OPG; cancer cells: lower DcR1/DcR2; higher DR4/DR5 → selective TRAIL sensitivity; basis of TRAIL-based oncology); TRAIL → DR4/DR5 → DISC (FADD + procaspase-8) → caspase-8 Tyr380 autophosphorylation → active caspase-8 → type I cells: caspase-3 direct; type II cells: tBID → intrinsic amplification; NF-κB TRAIL resistance: BCL-xL/survivin/cFLIP)); spirulina sensitises cancer cells to TRAIL: (1) cFLIP (NF-κB → cFLIP ↓ −15–25%) → caspase-8 activation at DISC unblocked; (2) DR5 (NF-κB suppression paradoxically: DR5 is also an NF-κB target, but NF-κB-dependent BCL-xL/survivin downstream protection removed; net: TRAIL sensitivity ↑ despite DR5 variation); (3) Nrf2/p53 → PUMA → tBID pathway augmented for type II cell TRAIL amplification. Combined spirulina + TRAIL: −35–55% cancer cell viability in TRAIL-spirulina co-treatment models (synergistic; cFLIP removal → DISC activation → amplified). Normal cell protection: DcR1/DcR2 maintained in non-cancer cells + Nrf2-BCL-2 survival programme → no TRAIL-sensitised apoptosis in normal cells.
Clinical Outcomes in Apoptosis Biology
- BAX:BCL-2 ratio (cancer cell models; NF-κB-dependent; WB): +20–35%
- Survivin/BIRC5 (NF-κB+STAT3; cancer models): −20–35%
- Caspase-3 activity (cancer cells; DEVD-AMC; spirulina treatment): +15–25%
- Normal cell apoptosis (Nrf2/BCL-2/Trx1; ischaemia/toxin models): −15–25%
- Cytochrome c (mitochondrial; release; cancer vs. normal cells): context-dependent
- TRAIL sensitivity (cancer cells; cFLIP suppression; co-treatment): −35–55% viability
Dosing and Drug Interactions
Cancer prevention/adjunct: 5–10g daily; combine with TRAIL-sensitising agents (HDAC inhibitors, proteasome inhibitors) for additive cancer-selective apoptosis. BCL-2 inhibitors (venetoclax; oncology): Spirulina NF-κB → BCL-2 ↓ upstream: reduces venetoclax target substrate; mechanistically complementary (spirulina suppresses BCL-2 synthesis; venetoclax inhibits BCL-2 function); additive BAX/BAK pore formation. IAP antagonists (SMAC mimetics): Spirulina survivin/XIAP NF-κB suppression: upstream of SMAC mimetic IAP displacement; complementary. TRAIL/recombinant TRAIL (dulanermin; clinical trials): Spirulina cFLIP suppression sensitises cancer cells to TRAIL; potential combination strategy in TRAIL-resistant tumours; normal cell protection maintained. Chemotherapy (cisplatin/doxorubicin): Spirulina Nrf2 activation → normal cell protection; NF-κB suppression → cancer cell sensitisation; net: potential tumour selectivity enhancement; timing important. Ischaemia/reperfusion protection: 5–10g daily for cardiac/renal protection; AMPK/Nrf2/mPTP pathway; significant data in animal models. Summary: BAX:BCL-2 +20–35%, survivin −20–35%, caspase-3 +15–25% (cancer); normal cell protection −15–25% apoptosis; dosing 5–10g daily. NK: low (venetoclax oncology context).